When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
From the U.S. FDA-approved label for Methylprednisolone. Full label: DailyMed.
When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
From the U.S. FDA-approved label for Methylprednisolone. Full label: DailyMed.
Use only Water for Injection or Bacteriostatic Water For Injection with Benzyl Alcohol when reconstituting methylprednisolone sodium succinate (see DESCRIPTION ). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. This preparation may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection.
Directions from the U.S. FDA-approved label for Methylprednisolone — your doctor or pharmacist may advise differently.
Methylprednisolone Sodium Succinate Sterile Powder is contraindicated: in systemic fungal infections and patients with known hypersensitivity to the product and its constituents; The methylprednisolone sodium succinate for injection 40 mg presentation includes lactose monohydrate produced from cow’s milk. This presentation is therefore contraindicated in patients with a known or suspected hypersensitivity to cow’s milk or its components or other dairy products because it may contain trace amounts of milk ingredients. for intrathecal administration.
Excerpt from the U.S. FDA-approved label for Methylprednisolone. Talk to a pharmacist or doctor before use.
Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use.
Warnings and precautions excerpt from the U.S. FDA-approved label for Methylprednisolone — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse reactions have been reported with methylprednisolone sodium succinate or other corticosteroids: Allergic reactions: Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema. Blood and lymphatic system disorders: Leukocytosis.
Excerpt from the U.S. FDA-approved label for Methylprednisolone — not a complete list. Talk to a pharmacist or doctor about side effects.
14 brands · 4 makers in the NepalDoc catalog — see the full Methylprednisolone guide →
CONDITIONS Protect from light. Store unreconstituted product at controlled room temperature 20° to 25°C (68° to 77°F). Store reconstituted solution (not further diluted) at controlled room temperature 20° to 25°C (68° to 77°F), and use it within 48 hours. See section DOSAGE AND ADMINISTRATION, for storage of further diluted solution.
Storage information from the U.S. FDA-approved label for Methylprednisolone.
What is Depo Medrol?
Depo Medrol 80mg/ml Injection is a Methylprednisolone medicine made by Pfizer Ltd. It comes as 80mg/ml Injection.
What is the generic name of Depo Medrol?
The generic name of Depo Medrol is Methylprednisolone.
Which brands of Methylprednisolone are available in Nepal?
14 brands of Methylprednisolone are listed in the NepalDoc catalog, from 4 makers — including Depo Medrol 40mg/ml Injection, Depopred 40mg Injection, Depopred 80mg Injection, Ivepred 1000mg Injection, Medrol 8mg Tablet, Medrol 16mg Tablet.
What are the side effects of Methylprednisolone?
The following adverse reactions have been reported with methylprednisolone sodium succinate or other corticosteroids: Allergic reactions: Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.
